July 25, 2019
Get insight from inThought Research experts on Novartis results from the phase 3 PARAGON-HF clinical trial evaluating Entresto versus valsartan in HFpEF.
- Novartis announced topline results from the phase 3 PARAGON-HF study evaluating Entresto versus valsartan in HFpEF.
- The primary endpoint of reducing cardiovascular death and total heart failure hospitalizations did not reach reach statistical significance.
- The data will be presented at the ESC Congress in September.
- Scott Solomon M.D., the trial co-chair, noted that the full trial results may results in clinically meaningful benefits in patients with HFpEF and that the company will discuss next steps with clinical experts and regulators.